Pharmaceutical Gelatin Market Size & Share Analysis - Emerging Trends, Growth Opportunities, Competitive Landscape, and Forecasts (2025 - 2032)

Pharmaceutical Gelatin Market Trends & Drivers

Increasing Demand for Functional Food and Nutraceuticals Is Key Trend

• The consumer demand for functional food has significantly increased in recent years, due to its nutritional advantages.
• Consumers' hectic lifestyles and constantly shifting purchasing intents for various food and beverage goods have increased the need for functional food, leading to the market growth.
• Nowadays, people are becoming more aware of food quality, as several health benefits are linked to diverse meals, and the popularity of functional food increases.
• As a consequence, consumers' interest in having nutritious meals has increased.
• Moreover, gelatin enhances the flavor, taste, nutritional value, and texture of vitamin supplements, helping in boosting the immunity of the body and supporting their sales.
• This expansion directly translates to an increase in the demand for pharmaceutical-grade gelatin as a key ingredient in dietary supplements, fortified gummies, and functional beverages.
• The convergence of food and pharmaceutical sectors, particularly in the delivery of bioactive compounds through consumer-friendly formats, positions gelatin as an essential excipient bridging nutritional and therapeutic applications.
• The shifts in consumers’ preferences toward preventive healthcare and natural remedies are increasing the demand for collagen-based supplements and gelatin-encapsulated nutraceuticals.
• This trend is particularly pronounced in aging populations seeking joint health, skin elasticity, and bone strength benefits through convenient oral dosage forms.
• The ability of gelatin capsules to protect sensitive bioactive ingredients while ensuring optimal bioavailability makes them the preferred delivery system for omega-3 fatty acids, probiotics, and fat-soluble vitamins.
• Furthermore, the clean-label movement in functional foods aligns perfectly with pharmaceutical gelatin's natural origin and established safety profile.
• Manufacturers are leveraging gelatin's multifunctional properties—including gelling, stabilizing, and film-forming capabilities—to develop innovative products that meet consumer demands for transparency and efficacy.
• In April 2025, Reunion Neuroscience Inc. unveiled the study design for its phase 2 clinical trial of RE104, incorporating specialized pharmaceutical gelatin formulations for treating adjustment disorder in cancer patients.
• The development of specialized gelatin grades for gummy vitamins and supplements, such as fast-setting formulations that enable starch-free production while maintaining sensory appeal, demonstrates the industry's responsiveness to market trends.
• This synergy between pharmaceutical expertise and consumer product innovation creates sustained demand growth for pharmaceutical gelatin across both traditional pharmaceutical and emerging nutraceutical applications.

Rising Chronic Disease Prevalence and Aging Population Are Biggest Drivers

• The escalating prevalence of chronic diseases globally and an aging population are the fundamental pharmaceutical gelatin market drivers.
• According to the WHO, non-communicable diseases were responsible for 41 million deaths annually, or 71% of all deaths globally.
• Of these, over 15 million deaths occur between the ages of 30 and 69, which are considered premature.
• Cardiovascular diseases lead this burden with at least 19.8 million deaths each year, followed by cancers (9.8 million), chronic respiratory diseases, and diabetes.
• The chronic disease epidemic particularly affects the aging population, who require long-term medication regimens delivered through various dosage forms, including capsules and tablets.
• Pharmaceutical gelatin plays a crucial role in these formulations, offering superior drug delivery capabilities and patient compliance.
• The shift toward soft gelatin capsules for chronic disease medications is particularly notable, as these forms provide better bioavailability and are easier to swallow compared to traditional tablets, making them ideal for elderly patients and those with swallowing difficulties.
• Furthermore, the economic impact of chronic diseases drives pharmaceutical innovation and investment in advanced drug delivery systems.
• With global prescription medication spending increasing by 6.0% to 8.0% annually, the demand for pharmaceutical-grade gelatin as a key excipient continues to surge.
• According to the United Nations, by the late 2070s, the global population aged 65 and older is projected to reach 2.2 billion, surpassing the number of children under age 18.
• More immediately, by 2030, 1 in 6 people worldwide will be aged 60 years or over, with this demographic increasing from 1 billion in 2020 to 1.4 billion.
• This demographic transition directly correlates with the increasing pharmaceutical consumption, as older adults typically require multiple medications for various age-related conditions.
• The elderly population's preference for easy-to-swallow dosage forms makes gelatin-based capsules particularly attractive.
• Hard gelatin capsules are popular due to their ability to mask unpleasant tastes and odors while providing consistent drug release profiles.
• Additionally, the growing use of dietary supplements and nutraceuticals among the aging population, delivered primarily through gelatin capsules, further amplifies the market growth potential.
• The impact of population aging is particularly pronounced in developed regions such as North America and Europe, where healthcare infrastructure supports extensive pharmaceutical use.
• However, the fastest growth in elderly populations is occurring in Asia-Pacific countries, creating new market opportunities.
• China and India are experiencing rapid demographic transitions, with their healthcare systems adapting to serve growing numbers of elderly patients, thereby driving demand for pharmaceutical gelatin in these emerging markets.

Pharmaceutical Gelatin Market Segmentation Analysis

Source Analysis

The porcine category held the largest market share, of 45%, in 2024, because it demonstrates clear preferences based on availability, cost-effectiveness, and functional properties. It has superior gelling properties, widespread availability, and cost advantages. The well-established supply chains for porcine gelatin, particularly in Western markets, combined with its excellent performance characteristics in both hard and soft capsule applications, sustain its market leadership. The consistent quality and standardized production processes for porcine gelatin make it the preferred choice for large-scale pharmaceutical manufacturers.

The marine category will have the highest CAGR, driven by the increasing demand for halal and kosher-certified products, particularly in Middle Eastern and Southeast Asian markets where religious dietary restrictions limit the use of porcine and bovine sources. Innovative processing techniques and recent technological improvements have enhanced marine gelatin’s gel strength, overcoming historical barriers to its use in capsule production. Additionally, concerns about transmissible spongiform encephalopathies associated with bovine sources and religious restrictions on porcine gelatin in Islamic countries have accelerated the adoption of marine alternatives, despite their traditionally higher production costs.

The sources analyzed in this report are:

• Porcine (Largest Category)
• Bovine
• Marine (Fastest-Growing Category)
• Poultry

Type Analysis

The type A category held the larger market share, of 85%, in 2024, derived primarily from porcine sources through acid processing. Its dominance stems from superior clarity, lower viscosity, and excellent compatibility with a wide range of active pharmaceutical ingredients. Type A gelatin's isoelectric point of 7-9 makes it particularly suitable for encapsulating acidic drugs and provides optimal performance in soft gelatin capsule applications where clarity and elasticity are paramount.

The type B category will have the higher CAGR, driven by its superior performance in specific pharmaceutical applications. Derived from bovine sources through alkaline processing, Type B offers enhanced stability in alkaline conditions and stronger tablet binding properties, making it increasingly preferred for sustained-release formulations and high drug-load matrices. The development of low-bloom Type B variants specifically designed for lipid nanoparticle vaccines aligns with WHO pharmacopeial purity requirements, opening new high-value market segments. Additionally, the growing focus on modified-release formulations and the expansion of biologics manufacturing favor Type B's unique rheological properties.

The types analyzed in this report are:

• Type A (Larger Category)
• Type B (Faster-Growing Category)

Application Analysis

The hard capsule category held the largest market share, of 40%, in 2024, This is attributed to the increase in the need for hard capsules globally, owing to the benefits of hard gelatin capsules for quick drug release and consistent mixing of drugs and others. Also, the gelatin used in hard capsules safeguards sensitive ingredients from oxygen, contamination, light, and microbial growth.

Additionally, the increasing consumption of over-the-counter (OTC) medicines, rising chronic diseases, and increasing initiatives from key players for the manufacturing of innovative gelatin capsule shells with the use of novel technology are driving the growth of the market. For instance, etectRx Inc. launched a MyTPill study to screen antiretroviral therapy adherence among users of prescription opioids and living with HIV. During the study, MyTPill can assess the adherence of patients by using two electronic adherence tracking technologies, namely, the ID-Cap System and an electronic pill box. This study provides insight into how digital pill systems can help patients who have significant health risks due to non-adherence. Such initiatives lead to the rise in the adoption of gelatin for producing hard gelatin capsules (ID-Cap).

The softgel capsules category will have the highest CAGR. This growth is fueled by increasing demand for enhanced bioavailability formulations, particularly for poorly water-soluble drugs and lipophilic compounds. The ability of soft gelatin capsules to deliver liquid and semi-solid formulations while providing superior content uniformity for low-dose drugs positions them favorably in the evolving pharmaceutical landscape. The expanding market for omega-3 supplements, fat-soluble vitamins, and cannabinoid-based medications particularly drives soft capsule demand, as these formulations offer optimal delivery mechanisms for oil-based active ingredients.

The applications analyzed in this report are:

• Hard Capsules (Largest Category)
• Softgel Capsules (Fastest-Growing Category)
• Tablets
• Absorbable Hemostats

Function Analysis

The stabilizing agent category held the largest market share, of 45%, in 2024, as a result of the surging use of gelatin as a stabilizer in the production of vaccines. Moreover, gelatin offers protection to vaccines from heat or freeze-drying in the process of delivery and transport. Additionally, the stabilizing agent inhibits the deformation of products and provides desired texture to them. As pharmaceutical formulations become more complex, especially biologics and combination products, the requirement for gelatin for stabilization is rising. Furthermore, the expansion of global vaccine programs and the development of thermostable vaccine formulations for distribution in resource-limited settings amplify demand for gelatin-based stabilizers.

The thickening agent category will have the highest CAGR, due to its usage in liquid dosage, syrups, lotions, and creams. This gelatin thickener offers excellent liquid viscosity without altering the properties of the final products. Additionally, the manufacturing of cosmetics frequently uses gelatin to thicken products and employed it as a stabilizer to slow down a product's melting rate.

The functions analyzed in this report are:

• Stabilizing Agent (Largest Category)
• Gelling Agent
• Thickening Agent (Fastest-Growing Category)
• Other Functions

End User Analysis

The pharmaceutical & biopharmaceutical companies category held the largest market share, of 65%, in 2024, due to the increasing use of pharmaceutical gelatin in drug discovery and various other applications in several industries. For example, gelatin is used in biomedical applications such as wound dressing and wound healing, cosmetic applications, tissue engineering, gene therapy, and implants and bone substitutes.

The biotechnology companies category will have the highest CAGR. This growth is propelled by the biotechnology sector's focus on innovative drug delivery systems and biologics that require specialized excipients. The development of personalized medicines, cell and gene therapies, and novel protein therapeutics creates unique formulation challenges where pharmaceutical gelatin's biocompatibility and functional versatility prove essential. Additionally, the increasing number of biotechnology companies entering late-stage clinical trials and commercialization phases translates directly into higher demand for GMP-grade pharmaceutical gelatin.

The end users analyzed in this report are:

• Pharmaceutical & Biopharmaceutical Companies (Largest Category)
• Biotechnology Companies (Fastest-Growing Category)
• Academic & Research Institutions

Pharmaceutical Gelatin Market Regional Market Performance

North America Pharmaceutical Gelatin Market Size

North America held the largest market share, of 40%, in 2024. This dominance is primarily attributed to the region's well-established pharmaceutical industry, substantial healthcare expenditure, and strong regulatory framework that emphasizes quality and safety in drug manufacturing. The presence of major pharmaceutical companies and contract manufacturing organizations, combined with advanced healthcare infrastructure, creates sustained demand for high-quality pharmaceutical gelatin across various applications.

Moreover, due to the technological advancements in drug manufacturing and high incidence rates of chronic illnesses and various other disorders in the U.S. and Canada, the need for advanced drugs is rising, which, in turn, the demand for pharmaceutical gelatin is increasing, because it is widely used as a stabilizer in vaccines for ensuring their safety and efficacy during storage and transportation.

The U.S. drives the North American market, benefiting from its position as a global pharmaceutical innovation hub. The country's robust investment in pharmaceutical R&D, coupled with the presence of leading gelatin manufacturers and advanced purification facilities, ensures a consistent supply of specialized grades for emerging applications.

Canada Pharmaceutical Gelatin Market Size

Canada's pharmaceutical gelatin market benefits from government initiatives supporting biomanufacturing and the country's growing elderly population. The nation's incentive programs for biotechnology have attracted new collagen hydrolysis pilot projects specifically targeting gene therapy stabilizers, expanding the market beyond traditional applications. Additionally, Canada's stringent quality standards and regulatory alignment with international requirements position it as a reliable supplier for specialized pharmaceutical gelatin grades to global markets.

Asia-Pacific Pharmaceutical Gelatin Market Size

Asia-Pacific will have the highest CAGR, of approx. 6.0%, during forecast period. This exceptional growth trajectory is driven by the rapid expansion of pharmaceutical manufacturing capabilities, increasing healthcare investments, and the region's large and aging population base. Countries such as China and India are emerging as major pharmaceutical production hubs, supported by government initiatives promoting domestic manufacturing and improving healthcare access. The region's growing middle class, coupled with increasing health awareness and disposable income, creates expanding demand for both prescription medications and nutraceutical products delivered through gelatin-based systems. Moreover, Japanese manufacturers contribute advanced technology and quality standards to the regional market, while South Korea's focus on biosimilars and innovative formulations creates demand for specialized gelatin grades.

China Pharmaceutical Gelatin Market Size

China's pharmaceutical industry is experiencing unprecedented growth, driven by government cost controls, an aging population, and rising disposable incomes. This expansion directly translates to increased demand for pharmaceutical gelatin, particularly as Chinese manufacturers upgrade facilities to meet international quality standards. The country's evolving regulatory landscape favors high-quality excipients, creating opportunities for both domestic and international gelatin suppliers. Additionally, China's traditional use of gelatin in various applications provides cultural acceptance that facilitates market penetration for pharmaceutical grades.

India Pharmaceutical Gelatin Market Size

India's pharmaceutical gelatin market benefits from its extensive generic drug, thereby requiring substantial volumes of pharmaceutical excipients. The expansion of contract manufacturing capabilities to serve global markets, combined with increasing domestic healthcare coverage, drives consistent demand growth.

As per the IBEF, India hosts the largest number of USFDA-compliant pharmaceutical plants outside of the U.S., along with over 2,000 WHO-GMP approved facilities and 10,500+ manufacturing units, serving over 150 countries. Moreover, pharmaceutical exports stood at USD 27.82 billion (INR 2,43,119 crore) in FY24, rising to USD 30.38 billion (INR 2,59,658 crore) in FY25. India is the largest provider of generic medicines globally, supplying around 20% of the global generic drug demand by volume and ~60% of the global vaccine supply.

The geographical breakdown of the market is as follows:

• North America (Largest Regional Market)
  • U.S. (Larger Country)
  • Canada (Faster-Growing Country)
• Europe
  • Germany (Largest Country)
  • U.K. (Fastest-Growing Country)
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific (Fastest-Growing Regional Market)
  • China (Largest Country)
  • India (Fastest-Growing Country)
  • Japan
  • South Korea
  • Australia
  • Rest of APAC
• Latin America
  • Brazil (Largest Country)
  • Mexico (Fastest-Growing Country)
  • Rest of LATAM
• Middle East and Africa
  • Saudi Arabia (Largest Country)
  • South Africa (Fastest-Growing Country)
  • U.A.E.
  • Rest of MEA

Pharmaceutical Gelatin Market Share Analysis

The market is fragmented due to the presence of several established players, each maintaining significant positions through specialized production capabilities, technological expertise, and global distribution networks. While the top companies hold a sizable share, numerous regional and niche manufacturers cater to specific applications or geographic markets. Additionally, high capital requirements, regulatory compliance, and the need for product differentiation create barriers, preventing a single player from dominating.

Pharmaceutical Gelatin Market News

• In July 2025, Nitta Gelatin India Limited announced an INR 200-crore expansion of its Kerala, India facility. The initiative includes a new gelatin unit, a modern collagen peptide plant, and new product lines aimed at the high-demand health and wellness market.
• In October 2024, Darling Ingredients Inc. launched Nextida GC collagen peptide as a bioactive health ingredient specifically for pharmaceutical applications. It offers enhanced bioavailability and controlled post-prandial glucose response support for diabetes management formulations.